Evidence map›Paper›PMID 34812690›Full record

ArticleInnate immunity2021

Bergamottin alleviates LPS-induced acute lung injury by inducing SIRT1 and suppressing NF-κB.

Ning An, Tao Yang, Xiao-Xia Zhang, Mei-Xia Xu

Open access · goldAbstract read
In one paragraph

Article in Innate immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ning AnInstitue of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, 12443Huazhong University of Science and Technology, Wuhan, China.
Tao YangDepartment of Intensive Care Unit, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, 12443Huazhong University of Science and Technology, Wuhan, China.
Xiao-Xia ZhangDepartment of Intensive Care Unit, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, 12443Huazhong University of Science and Technology, Wuhan, China.
Mei-Xia XuDepartment of Intensive Care Unit, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, 12443Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0003-2667-1577
Wuhan Puai Hospital · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lung injury (ALI) is associated with a high mortality due to inflammatory cell infiltration and lung edema. The development of ALI commonly involves the activation of NF-κB. Since bergamottin is a natural furanocoumarin showing the ability to inhibit the activation of NF-κB, in this study we aimed to determine the effect of bergamottin on ALI. RAW264.7 mouse macrophages were pre-treated with bergamottin and then stimulated with LPS. Macrophage inflammatory responses were examined. Bergamottin (50 mg/kg body mass) was intraperitoneally administrated to mice 12 h before injection of LPS, and the effect of bergamottin on LPS-induced ALI was evaluated. Our results showed that LPS exposure led to increased production of TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1), which was impaired by bergamottin pre-treatment.

Indexed as

Acute Lung InjuryFurocoumarinsAnimalsBronchoalveolar Lavage FluidCytokinesLipopolysaccharidesLungMiceNF-kappa BSirtuin 1bergamottinCytokinesFurocoumarinsLipopolysaccharidesNF-kappa BSirt1 protein, mouseSirtuin 1Acetylationbergamottinlung inflammationNF-κBSIRT1

Identifiers

PMID34812690
PMCPMC8762093
OpenAlexW3216291032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.